Introduction
The treatment of rheumatic heart disease uses a combination of infection control, anti-inflammatory therapy, management of heart failure and arrhythmias, prevention of recurrent rheumatic fever, and, in advanced cases, valve repair or replacement. These treatments are directed at the biological processes that drive the disease: immune-mediated inflammation after group A streptococcal infection, progressive scarring and deformation of heart valves, and the hemodynamic consequences of narrowed or leaky valves.
Rheumatic heart disease is the chronic structural result of repeated or severe episodes of rheumatic fever. The heart valves, most often the mitral valve and sometimes the aortic valve, become thickened, fused, shortened, or distorted. Treatment therefore aims to reduce inflammation when active disease is present, prevent new streptococcal infections that can trigger further immune injury, relieve symptoms caused by abnormal blood flow, and restore valve function when damage becomes severe.
Understanding the Treatment Goals
The central treatment goals are to reduce symptoms, limit progression of valve damage, prevent complications, and preserve cardiac function for as long as possible. Because the main problem in rheumatic heart disease is not an ongoing infection in the heart itself but the long-term structural damage left behind by immune injury, treatment often focuses on controlling the consequences of that damage rather than reversing it completely.
Early in the disease process, treatment may target active inflammation from rheumatic fever and the underlying streptococcal trigger. In later stages, the priority shifts to managing the mechanical effects of damaged valves. Stenotic valves obstruct forward blood flow, while regurgitant valves allow blood to leak backward. These changes increase pressure in the chambers above the valve, cause chamber enlargement, raise pulmonary pressures, and weaken pump efficiency. Treatment choices are therefore guided by how much the valve defect disturbs circulation, whether the patient has symptoms, and whether complications such as atrial fibrillation, pulmonary hypertension, or heart failure have developed.
Common Medical Treatments
Secondary antibiotic prophylaxis is one of the most important long-term treatments. It usually involves regular antibiotics, often penicillin-based, to prevent repeated group A streptococcal throat infections. The biological logic is straightforward: each new streptococcal infection can reactivate the immune response that led to rheumatic fever, increasing the risk of further valvular injury. By reducing exposure to the bacterial trigger, prophylaxis lowers the chance of additional inflammatory episodes and slows cumulative valve scarring.
Antibiotics for active streptococcal infection are used when a throat infection or another streptococcal focus is identified. These drugs eliminate the bacteria that provide the antigenic stimulus for the immune response. They do not directly treat the valve lesion, but they interrupt the chain of events that can lead to fresh immune-mediated damage.
Anti-inflammatory treatment, typically with aspirin or other nonsteroidal anti-inflammatory drugs, may be used during acute rheumatic fever when inflammatory symptoms are present. Corticosteroids are sometimes used in severe inflammatory cases. These medicines suppress inflammatory signaling, reduce swelling in affected tissues, and decrease immune-mediated tissue injury. Their role is strongest during the active inflammatory phase of rheumatic disease, not in fixed chronic valve scarring. By lowering inflammation, they can reduce fever, joint symptoms, and, in some cases, the intensity of carditis.
Diuretics are commonly used when valve disease leads to congestion or heart failure. They increase renal excretion of sodium and water, reducing circulating blood volume and venous pressure. This lowers filling pressures in the heart and lungs, easing breathlessness and edema. Diuretics do not correct the valve lesion itself, but they reduce the hemodynamic burden caused by backward flow or obstructed forward flow.
Rate control medications, such as beta-blockers, calcium channel blockers, or digoxin in selected cases, may be used when atrial fibrillation or fast heart rates develop. Damaged valves, especially mitral stenosis, enlarge the left atrium and create conditions that favor atrial fibrillation. A rapid ventricular rate shortens filling time and worsens cardiac output. Rate control slows the heart, improves diastolic filling, and reduces the mismatch between oxygen demand and supply.
Anticoagulation is used in some patients with atrial fibrillation, prior embolic events, or marked atrial enlargement. Rheumatic valve disease, particularly mitral stenosis, promotes blood stasis in the atria, increasing the risk of clot formation. Anticoagulants reduce the ability of coagulation proteins to generate fibrin, thereby lowering the risk of stroke and systemic embolism. This treatment addresses a complication of altered flow rather than the valve pathology itself.
Afterload and blood pressure management may be used in patients with associated hypertension or with regurgitant lesions where reduced systemic resistance can lessen the volume of backward flow. The physiological effect is to decrease the pressure against which the left ventricle ejects blood, which can improve forward output in certain contexts. The exact choice depends on the valve lesion and overall cardiac function.
Procedures or Interventions
When valve damage becomes hemodynamically significant, procedural treatment may be required. The most common intervention for suitable patients with rheumatic mitral stenosis is percutaneous balloon mitral valvotomy. A catheter is threaded into the heart and a balloon is inflated across the narrowed valve. In rheumatic disease, the valve commissures are often fused, so balloon expansion separates these fused areas and increases the valve opening. This directly lowers the pressure gradient across the mitral valve and improves blood flow from the left atrium to the left ventricle. It is most effective when the valve is pliable and has limited calcification or severe regurgitation.
Surgical valve repair may be used when anatomy allows preservation of the native valve. Repair can involve commissurotomy, chordal procedures, or reshaping of valve leaflets. The aim is to restore more normal valve geometry and function while keeping the patient’s own tissue. Repair is less common in advanced rheumatic disease than in some other valve disorders because rheumatic scarring often produces diffuse thickening and restricted motion.
Valve replacement is used when the valve is too damaged to repair or when stenosis or regurgitation is severe enough to cause major symptoms, chamber remodeling, or ventricular dysfunction. Replacing the diseased valve removes the mechanically abnormal structure and substitutes a prosthetic valve that restores more normal flow. Mechanical valves are durable but require long-term anticoagulation because their surfaces can trigger clot formation. Bioprosthetic valves generally need less intense anticoagulation but are more likely to deteriorate over time. The choice reflects a balance between durability, thrombosis risk, bleeding risk, and patient factors.
In some patients, procedures are also used to treat complications of valve disease. For example, patients with atrial fibrillation may undergo rhythm or rate-related interventions, and those with severe pulmonary hypertension or heart failure may require specialized management before or after valve intervention. These approaches aim to correct the downstream effects of abnormal valvular hemodynamics.
Supportive or Long-Term Management Approaches
Rheumatic heart disease usually requires long-term follow-up because the condition evolves over years. Repeated clinical assessment and echocardiography are used to monitor valve morphology, pressure gradients, chamber size, ventricular function, and pulmonary pressures. This surveillance identifies progression before irreversible dysfunction becomes advanced. Imaging provides a structural view of the disease, while examination and symptom patterns show how the structure is affecting circulation.
Long-term antibiotic prophylaxis is a central supportive strategy because the disease is driven by immune memory to streptococcal antigens. Preventing reinfection reduces the chance of renewed inflammatory activation. In practice, this approach is most valuable in children and young adults, who are at highest risk for recurrent rheumatic fever and progressive damage.
Management of heart failure symptoms is often ongoing. Diuretics, rate-control drugs, and other cardiovascular medicines are used to reduce the physiologic strain created by valve dysfunction. These treatments do not heal the valve, but they can improve the balance between circulating volume, filling pressures, and pump performance, which is essential in chronic valvular disease.
Supportive care also includes attention to associated conditions that can intensify cardiac workload, such as anemia, hypertension, or pregnancy-related hemodynamic stress. These factors matter because rheumatic valve lesions reduce the heart’s reserve. Any additional increase in volume demand or heart rate can expose the limited efficiency of the damaged valve and worsen symptoms.
Factors That Influence Treatment Choices
Treatment depends heavily on the severity and stage of disease. Mild valve involvement without symptoms may be managed primarily with surveillance and prophylaxis, while severe stenosis or regurgitation may require intervention. The key issue is whether the valve lesion is causing significant obstruction, leakage, chamber enlargement, or impaired ventricular function.
The specific valve involved also matters. Mitral stenosis has different hemodynamic consequences from mitral regurgitation or aortic valve disease. Stenosis produces a pressure barrier to forward flow, whereas regurgitation causes volume overload. These different patterns explain why medications and procedures are selected differently in each case.
Age and overall health influence whether a patient is better suited to balloon valvotomy, surgical repair, or replacement. Younger patients may benefit from procedures that preserve native tissue when possible, while older patients or those with heavily calcified valves may need replacement. Pregnancy, bleeding risk, prior stroke, kidney disease, and other conditions also affect choices, especially when anticoagulation is required.
Prior response to treatment is another determinant. Some patients remain stable for years on prophylaxis and medical therapy, while others develop recurrent inflammation, worsening valve gradients, or arrhythmias despite treatment. In such cases, the threshold for procedural intervention becomes lower because the physiologic burden of the lesion is already overwhelming compensatory mechanisms.
Potential Risks or Limitations of Treatment
Medical treatment has limits because it cannot reverse established valvular scarring. Antibiotic prophylaxis prevents new damage but does not repair fibrotic shortening or fusion of valve leaflets. Anti-inflammatory drugs can reduce active inflammation, but they do not eliminate the chronic anatomical changes created by previous episodes.
Diuretics may relieve congestion, but they can also reduce effective circulating volume too much if overused, impairing perfusion. Rate-control drugs can improve filling, but excessive slowing of the heart may reduce cardiac output in some patients. Anticoagulation reduces embolic risk, but it increases bleeding risk because it interferes with clotting pathways needed for hemostasis.
Procedural treatments carry their own risks. Balloon valvotomy can cause valve regurgitation if the leaflets or chordae are torn or stretched excessively. Surgical repair or replacement involves anesthesia, cardiopulmonary bypass, bleeding risk, infection risk, and recovery from major chest or thoracic surgery. Prosthetic valves can thrombose, degenerate, or require reoperation over time. Mechanical valves create lifelong anticoagulation needs, which introduces a chronic bleeding hazard. Bioprosthetic valves avoid some of these issues but usually wear out sooner, especially in younger patients.
Another limitation is that advanced pulmonary hypertension or severe ventricular dysfunction may persist even after the valve is corrected, because prolonged abnormal loading can produce secondary remodeling in the lungs and heart muscle. For that reason, timing matters: intervention is more effective before irreversible structural and vascular changes become fixed.
Conclusion
The treatment of rheumatic heart disease is aimed at controlling the consequences of prior immune injury and preventing further damage. Antibiotics reduce the streptococcal trigger for recurrent rheumatic fever, anti-inflammatory drugs suppress active inflammation, and cardiovascular medicines relieve the hemodynamic effects of valve dysfunction. When structural valve damage becomes severe, balloon valvotomy or surgery can restore more normal flow by directly altering the abnormal anatomy.
Overall, treatment works by targeting the biological processes that drive symptoms and progression: immune activation, valve scarring, altered pressure and volume loading, arrhythmia, clot formation, and heart failure. Because the disease is fundamentally structural once chronic valve damage is established, long-term management combines prevention of new injury with correction of the mechanical consequences of the damaged valves.